Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer

被引：0
|
作者：
Hanne Vos
Kathleen Lambein
François Richard
Bram Mariën
Ines Nevelsteen
Kevin Punie
Hans Wildiers
Lieze Berben
Annouschka Laenen
Giuseppe Floris
Christine Desmedt
Ann Smeets
机构：
[1] University Hospitals Leuven; Department of Oncology,Department of Surgical Oncology
[2] KU Leuven,Laboratory for Translational Breast Cancer Research, Department of Oncology
[3] KU Leuven,Multidisciplinary Breast Centre
[4] University Hospitals Leuven,Laboratory of Experimental Oncology, Department of General Medical Oncology
[5] University Hospitals Leuven,Leuven Biostatistics and Statistical Bioinformatics Centre (L
[6] KU Leuven,BioStat)
[7] KU Leuven,Laboratory of Translational Cell & Tissue Research, Department of Imaging and Pathology, University Hospitals Leuven
[8] KU Leuven,undefined
来源：
npj Breast Cancer | / 7卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The vast majority of studies investigating immune checkpoint inhibition (ICI) in patients with breast cancer have focused on triple-negative breast cancer (TNBC). In this study, we compared the tumor immune microenvironment (TIME) between TNBC and hormone receptor-negative HER2-positive breast cancer based on a selection of immune markers at the protein level in an institutional retrospective series. Additionally, we performed a similar comparison using publicly available transcriptomics data. Altogether, the results show a comparable TIME in both groups, with possible implications for the use of ICI in patients with hormone receptor-negative HER2-positive breast tumors.
引用
收藏
相关论文
共 50 条
  • [41] Correlation between magnetic resonance imaging and the level of tumor-infiltrating lymphocytes in patients with estrogen receptor-negative HER2-positive breast cancer
    Choi, Woo Jung
    Kim, Youyeon
    Cha, Joo Hee
    Shin, Hee Jung
    Chae, Eun Young
    Yoon, Ga Young
    Kim, Hak Hee
    ACTA RADIOLOGICA, 2020, 61 (01) : 3 - 10
  • [42] Implications of high tumor infiltrating lymphocytes (TIL) in HER2-positive and triple-negative breast cancer (TNBC).
    Kotoula, Vassiliki
    Chatzopoulos, Kyriakos
    Lakis, Sotiris
    Alexopoulou, Zoi
    Timotheadou, Eleni
    Zagouri, Flora
    Pentheroudakis, George E.
    Gogas, Helen
    Galani, Eleni P.
    Tsolaki, Eleftheria
    Chrisafi, Sofia
    Koutras, Angelos
    Aravantinos, Gerasimos
    Papakostas, Pavlos
    Kosmidis, Paris A.
    Pectasides, Dimitrios G.
    Fountzilas, George
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [43] Clinical considerations for estrogen receptor-negative/ progesterone receptor-positive/HER2-negative (ER-PR+HER2-) breast cancer
    Rala de Paula, Bruno Henrique
    Crocamo, Susanne
    Bines, Jose
    TRANSLATIONAL BREAST CANCER RESEARCH, 2023, 4
  • [44] Metronomic Schedule of Paclitaxel Is Effective in Hormone Receptor-Positive and Hormone Receptor-Negative Breast Cancer
    Mehta, Rita S.
    Jackson, Donna
    Schubbert, Toni
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18) : 3067 - 3068
  • [45] Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer
    Ke-Da Yu
    Yi-Zhou Jiang
    Shuang Hao
    Zhi-Ming Shao
    BMC Medicine, 13
  • [46] Immune function and response to neoadjuvant chemotherapy in hormone receptor positive, HER2-negative breast cancer
    Matikas, A.
    Lovrot, J.
    Ramberg, A.
    Eriksson, M.
    Lindsten, T.
    Lekberg, T.
    Hedenfalk, I.
    Loman, N.
    Bergh, J.
    Erlandsson, A.
    Hatschek, T.
    Foukakis, T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [47] Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer
    Yu, Ke-Da
    Jiang, Yi-Zhou
    Hao, Shuang
    Shao, Zhi-Ming
    BMC MEDICINE, 2015, 13
  • [48] New Treatment Options in ER-Positive, HER2-Positive and Triple-Negative Breast Cancer
    Steger, Guenther
    Bell, Richard
    Cameron, David
    Dent, Rebecca A.
    Jackisch, Christian
    BREAST CARE, 2013, 8 (02) : 155 - 157
  • [49] Immunotherapy for hormone receptor-positive HER2-negative breast cancer
    Cardoso, Fatima
    Hirshfield, Kim M.
    Kraynyak, Kimberly A.
    Tryfonidis, Konstantinos
    Bardia, Aditya
    NPJ BREAST CANCER, 2024, 10 (01)
  • [50] COMPARISON OF CLASSIC AND QUANTITATIVE PROGNOSTIC FACTORS IN HORMONE RECEPTOR-POSITIVE AND HORMONE RECEPTOR-NEGATIVE FEMALE BREAST-CANCER
    AALTOMAA, S
    LIPPONEN, P
    ESKELINEN, M
    KOSMA, VM
    MARIN, S
    ALHAVA, E
    SYRJANEN, K
    AMERICAN JOURNAL OF SURGERY, 1993, 165 (03): : 307 - 311
12345